CONVERTIBLE DEBENTURES	6 Months Ended
May 31, 2013
Debt Disclosure [Abstract]
Long-term Debt [Text Block]	NOTE 3. CONVERTIBLE DEBENTURES MultiCell entered into a Securities Purchase Agreement with LJCI on February 28, 2007 (the “LJCI Agreement”), pursuant to which MultiCell agreed to sell a convertible debenture to LJCI in the principal amount of $100,000 and originally scheduled to mature on February 28, 2012 (the “Debenture”). On August 16, 2011, MultiCell and LJCI amended the Debenture to extend the maturity date to February 28, 2014. The Debenture accrues interest at 4.75% per year, payable in cash or common stock at the option of LJCI. In connection with the Debenture, MultiCell issued LJCI a warrant to purchase up to 10 million shares of the Company’s common stock (the “LJCI Warrant”) at an exercise price of $1.09 per share, exercisable over the next five years according to a schedule described in a letter agreement dated February 28, 2007. On August 16, 2011, MultiCell and LJCI amended the LJCI Warrant to extend the expiration date to February 28, 2014. Pursuant to the terms of the LJCI Warrant, upon the conversion of any portion of the principal amount of the Debenture, LJCI is required to simultaneously exercise and purchase that same percentage of the warrant shares equal to the percentage of the dollar amount of the Debenture being converted. Therefore, as an example, for each $1,000 of the principal converted, LJCI would be required to simultaneously purchase 100,000 shares under the LJCI Warrant at $1.09 per share. The Debenture is convertible at the option of LJCI at any time up to maturity into the number of shares determined by the dollar amount of the Debenture being converted multiplied by 110, minus the product of the Conversion Price (as defined below) multiplied by 100 times the dollar amount of the Debenture being converted, with the entire result divided by the Conversion Price. The “Conversion Price” is equal to the lesser of $1.00 or 80% of the average of the three lowest volume-weighted average prices during the twenty trading days prior to the election to convert. LJCI converted $5,780 and $4,510 of the Debenture into 594,747,473 and 144,291,494 shares, respectively, of the Company’s common stock during the six months ended May 31, 2013 and 2012, respectively. Simultaneously with these conversions, LJCI exercised warrants to purchase 578,000 shares and 451,000 shares of the Company’s common stock during the six months ended May 31, 2013 and 2012, respectively. Proceeds from the exercise of the warrants were $630,020 and $491,590 for the six months ended May 31, 2013 and 2012, respectively. At times, LJCI makes advances to MultiCell prior to the exercise of warrants. At May 31, 2013 and November 30, 2012, LJCI had advanced $0 and $50,000, respectively, to MultiCell in advance of LJCI’s exercise of warrants. At May 31, 2013 MultiCell had a receivable from LJCI of $1,805 for proceeds from LJCI’s exercise of warrants in excess of advances previously received. As of May 31, 2013, the remainder of the Debenture in the amount of $50,246 could have been converted by LJCI into approximately 5.8 billion shares of the Company’s common stock, which would require LJCI to simultaneously exercise and purchase all of the remaining 5,024,629 shares of the Company’s common stock under the LJCI Warrant at $1.09 per share. As of November 30, 2012, the balance of the Debenture was $56,026. For the Debenture, upon receipt of a conversion notice from the holder, MultiCell may elect to immediately redeem that portion of the Debenture that the holder elected to convert in such conversion notice, plus accrued and unpaid interest. MultiCell, at its sole discretion, has the right, without limitation or penalty, to redeem the outstanding principal amount of the Debenture not yet converted by the holder into common stock, plus accrued and unpaid interest thereon.

NOTE 3. CONVERTIBLE DEBENTURES

MultiCell entered into a Securities Purchase Agreement with LJCI on February 28, 2007 (the “LJCI Agreement”), pursuant to which MultiCell agreed to sell a convertible debenture to LJCI in the principal amount of $100,000 and originally scheduled to mature on February 28, 2012 (the “Debenture”). On August 16, 2011, MultiCell and LJCI amended the Debenture to extend the maturity date to February 28, 2014. The Debenture accrues interest at 4.75% per year, payable in cash or common stock at the option of LJCI. In connection with the Debenture, MultiCell issued LJCI a warrant to purchase up to 10 million shares of the Company’s common stock (the “LJCI Warrant”) at an exercise price of $1.09 per share, exercisable over the next five years according to a schedule described in a letter agreement dated February 28, 2007. On August 16, 2011, MultiCell and LJCI amended the LJCI Warrant to extend the expiration date to February 28, 2014. Pursuant to the terms of the LJCI Warrant, upon the conversion of any portion of the principal amount of the Debenture, LJCI is required to simultaneously exercise and purchase that same percentage of the warrant shares equal to the percentage of the dollar amount of the Debenture being converted. Therefore, as an example, for each $1,000 of the principal converted, LJCI would be required to simultaneously purchase 100,000 shares under the LJCI Warrant at $1.09 per share.

The Debenture is convertible at the option of LJCI at any time up to maturity into the number of shares determined by the dollar amount of the Debenture being converted multiplied by 110, minus the product of the Conversion Price (as defined below) multiplied by 100 times the dollar amount of the Debenture being converted, with the entire result divided by the Conversion Price. The “Conversion Price” is equal to the lesser of $1.00 or 80% of the average of the three lowest volume-weighted average prices during the twenty trading days prior to the election to convert. LJCI converted $5,780 and $4,510 of the Debenture into 594,747,473 and 144,291,494 shares, respectively, of the Company’s common stock during the six months ended May 31, 2013 and 2012, respectively. Simultaneously with these conversions, LJCI exercised warrants to purchase 578,000 shares and 451,000 shares of the Company’s common stock during the six months ended May 31, 2013 and 2012, respectively. Proceeds from the exercise of the warrants were $630,020 and $491,590 for the six months ended May 31, 2013 and 2012, respectively. At times, LJCI makes advances to MultiCell prior to the exercise of warrants. At May 31, 2013 and November 30, 2012, LJCI had advanced $0 and $50,000, respectively, to MultiCell in advance of LJCI’s exercise of warrants. At May 31, 2013 MultiCell had a receivable from LJCI of $1,805 for proceeds from LJCI’s exercise of warrants in excess of advances previously received.

As of May 31, 2013, the remainder of the Debenture in the amount of $50,246 could have been converted by LJCI into approximately 5.8 billion shares of the Company’s common stock, which would require LJCI to simultaneously exercise and purchase all of the remaining 5,024,629 shares of the Company’s common stock under the LJCI Warrant at $1.09 per share. As of November 30, 2012, the balance of the Debenture was $56,026. For the Debenture, upon receipt of a conversion notice from the holder, MultiCell may elect to immediately redeem that portion of the Debenture that the holder elected to convert in such conversion notice, plus accrued and unpaid interest. MultiCell, at its sole discretion, has the right, without limitation or penalty, to redeem the outstanding principal amount of the Debenture not yet converted by the holder into common stock, plus accrued and unpaid interest thereon.